Published in Evid Based Complement Alternat Med on December 05, 2012
Adverse events of herbal food supplements for body weight reduction: systematic review. Obes Rev (2005) 1.93
Amiodarone: review of pulmonary effects and toxicity. Drug Saf (2010) 1.92
Plants and the central nervous system. Pharmacol Biochem Behav (2003) 1.43
Impact of obesity on cardiovascular disease. Endocrinol Metab Clin North Am (2008) 1.26
Effects of encapsulated green tea and Guarana extracts containing a mixture of epigallocatechin-3-gallate and caffeine on 24 h energy expenditure and fat oxidation in men. Br J Nutr (2005) 1.16
Dramatic inhibition of amiodarone metabolism induced by grapefruit juice. Br J Clin Pharmacol (2000) 1.13
An herbal supplement containing Ma Huang-Guarana for weight loss: a randomized, double-blind trial. Int J Obes Relat Metab Disord (2001) 1.07
Guarana (Paullinia cupana) improves fatigue in breast cancer patients undergoing systemic chemotherapy. J Altern Complement Med (2011) 1.07
In vitro transdermal delivery of caffeine, theobromine, theophylline and catechin from extract of Guarana, Paullinia Cupana. Int J Pharm (2006) 1.04
Efficacy of 12 weeks supplementation of a botanical extract-based weight loss formula on body weight, body composition and blood chemistry in healthy, overweight subjects--a randomised double-blind placebo-controlled clinical trial. Eur J Med Res (2006) 0.96
Prevalence of potentially hazardous drug interactions amongst Australian veterans. Br J Clin Pharmacol (2010) 0.96
Amiodarone as paradigm for developing new drugs for atrial fibrillation. J Cardiovasc Pharmacol (2008) 0.89
Obesity and cardiovascular risk: the new public health problem of worldwide proportions. Expert Rev Cardiovasc Ther (2004) 0.87
Habitual intake of guaraná and metabolic morbidities: an epidemiological study of an elderly Amazonian population. Phytother Res (2011) 0.85
Lipid metabolism in trained rats: effect of guarana (Paullinia cupana Mart.) supplementation. Clin Nutr (2005) 0.85
Acute and subchronic toxicological evaluation of the semipurified extract of seeds of guaraná (Paullinia cupana) in rodents. Food Chem Toxicol (2010) 0.85
Amiodarone for the treatment and prevention of ventricular fibrillation and ventricular tachycardia. Vasc Health Risk Manag (2010) 0.85
Pharmacokinetics of Amiodarone in hyperlipidemic and simulated high fat-meal rat models. Biopharm Drug Dispos (2005) 0.83
A novel property of an aqueous guaraná extract (Paullinia cupana): inhibition of platelet aggregation in vitro and in vivo. Braz J Med Biol Res (1988) 0.83
Development of an analytical method using reversed-phase HPLC-PDA for a semipurified extract of Paullinia cupana var. sorbilis (guaraná). Talanta (2011) 0.83
A novel dietary supplement containing multiple phytochemicals and vitamins elevates hepatorenal and cardiac antioxidant enzymes in the absence of significant serum chemistry and genomic changes. Oxid Med Cell Longev (2010) 0.82
Strategies to reduce vascular risk associated with obesity. Curr Vasc Pharmacol (2007) 0.80
Effects of orlistat, a lipase inhibitor, on the pharmacokinetics of three highly lipophilic drugs (amiodarone, fluoxetine, and simvastatin) in healthy volunteers. J Clin Pharmacol (2003) 0.80
Bioavailability of amiodarone tablets administered with and without food in healthy subjects. Am J Cardiol (2001) 0.80
Pharmacokinetics of desethylamiodarone in the rat after its administration as the preformed metabolite, and after administration of amiodarone. Biopharm Drug Dispos (2008) 0.79
Results of a safety initiative for patients on concomitant amiodarone and simvastatin therapy in a Veterans Affairs medical center. J Manag Care Pharm (2010) 0.79
The effect of beta-naphthoflavone on the metabolism of amiodarone by hepatic and extra-hepatic microsomes. Toxicol Lett (2010) 0.78
An evaluation of the early pharmacodynamic response after simultaneous initiation of warfarin and amiodarone. J Clin Pharmacol (2010) 0.77
An aqueous extract of guaraná (Paullinia cupana) decreases platelet thromboxane synthesis. Braz J Med Biol Res (1991) 0.77
A rapid HPLC method for the simultaneous determination of amiodarone and its major metabolite in rat plasma and tissues: a useful tool for pharmacokinetic studies. J Chromatogr Sci (2012) 0.77
Understanding physician antibiotic prescribing behaviour: a systematic review of qualitative studies. Int J Antimicrob Agents (2012) 1.87
Intranasal drug delivery: how, why and what for? J Pharm Pharm Sci (2009) 1.63
Pharmacokinetic and safety profile of trans-resveratrol in a rising multiple-dose study in healthy volunteers. Mol Nutr Food Res (2009) 1.47
Cognitive and behavioural effects of physical exercise in psychiatric patients. Prog Neurobiol (2011) 1.18
Pharmacokinetics of trans-resveratrol following repeated administration in healthy elderly and young subjects. J Clin Pharmacol (2009) 1.14
Long-term safety and efficacy of eslicarbazepine acetate as adjunctive therapy in the treatment of partial-onset seizures in adults with epilepsy: results of a 1-year open-label extension study. Epilepsy Res (2012) 1.03
Use of off-label and unlicenced drugs in hospitalised paediatric patients: a systematic review. Eur J Clin Pharmacol (2014) 1.03
Workshop- and telephone-based interventions to improve adverse drug reaction reporting: a cluster-randomized trial in Portugal. Drug Saf (2012) 0.98
Efficacy and safety of eslicarbazepine acetate as add-on treatment in patients with focal-onset seizures: integrated analysis of pooled data from double-blind phase III clinical studies. Epilepsia (2012) 0.98
Steady-state plasma and cerebrospinal fluid pharmacokinetics and tolerability of eslicarbazepine acetate and oxcarbazepine in healthy volunteers. Epilepsia (2012) 0.96
Association between white matter fiber integrity and subclinical psychotic symptoms in schizophrenia patients and unaffected relatives. Schizophr Res (2012) 0.93
Single-dose and steady-state pharmacokinetics of eslicarbazepine acetate (BIA 2-093) in healthy elderly and young subjects. J Clin Pharmacol (2005) 0.93
Safety, tolerability, and pharmacokinetics of etamicastat, a novel dopamine-β-hydroxylase inhibitor, in a rising multiple-dose study in young healthy subjects. Drugs R D (2010) 0.85
Effects of nebicapone on levodopa pharmacokinetics, catechol-O-methyltransferase activity, and motor fluctuations in patients with Parkinson disease. Clin Neuropharmacol (2008) 0.84
Single-dose tolerability, pharmacokinetics, and pharmacodynamics of etamicastat (BIA 5-453), a new dopamine β-hydroxylase inhibitor, in healthy subjects. J Clin Pharmacol (2012) 0.83
Dosage form proportionality and food effect of the final tablet formulation of eslicarbazepine acetate: randomized, open-label, crossover, single-centre study in healthy volunteers. Drugs R D (2008) 0.83
Pharmacokinetics, pharmacodynamics and tolerability of opicapone, a novel catechol-O-methyltransferase inhibitor, in healthy subjects: prediction of slow enzyme-inhibitor complex dissociation of a short-living and very long-acting inhibitor. Clin Pharmacokinet (2013) 0.82
Opicapone: a short lived and very long acting novel catechol-O-methyltransferase inhibitor following multiple dose administration in healthy subjects. Br J Clin Pharmacol (2013) 0.82
Effect of eslicarbazepine acetate on the pharmacokinetics of digoxin in healthy subjects. Fundam Clin Pharmacol (2009) 0.81
Third and fourth generation fluoroquinolone antibacterials: a systematic review of safety and toxicity profiles. Curr Drug Saf (2014) 0.81
CA-125 AUC as a predictor for epithelial ovarian cancer relapse. Cancer Biomark (2008) 0.81
Evaluation of the permeability and P-glycoprotein efflux of carbamazepine and several derivatives across mouse small intestine by the Ussing chamber technique. Epilepsia (2012) 0.81
Effect of opicapone and entacapone upon levodopa pharmacokinetics during three daily levodopa administrations. Eur J Clin Pharmacol (2014) 0.81
Pharmacokinetic interaction study between eslicarbazepine acetate and topiramate in healthy subjects. Curr Med Res Opin (2010) 0.80
Cognitive disconnective syndrome by single strategic strokes in vascular dementia. J Neurol Sci (2012) 0.79
Pharmacokinetics and tolerability of eslicarbazepine acetate and oxcarbazepine at steady state in healthy volunteers. Epilepsia (2013) 0.79
Effect of moderate liver impairment on the pharmacokinetics of opicapone. Eur J Clin Pharmacol (2013) 0.79
Liquid chromatographic methods for the quantification of catecholamines and their metabolites in several biological samples--a review. Anal Chim Acta (2012) 0.79
Investigating herb-drug interactions: the effect of Citrus aurantium fruit extract on the pharmacokinetics of amiodarone in rats. Food Chem Toxicol (2013) 0.78
First HPLC-UV method for rapid and simultaneous quantification of phenobarbital, primidone, phenytoin, carbamazepine, carbamazepine-10,11-epoxide, 10,11-trans-dihydroxy-10,11-dihydrocarbamazepine, lamotrigine, oxcarbazepine and licarbazepine in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci (2013) 0.78
Development and validation of an HPLC-UV method for the simultaneous quantification of carbamazepine, oxcarbazepine, eslicarbazepine acetate and their main metabolites in human plasma. Anal Bioanal Chem (2010) 0.77
A rapid HPLC method for the simultaneous determination of amiodarone and its major metabolite in rat plasma and tissues: a useful tool for pharmacokinetic studies. J Chromatogr Sci (2012) 0.77
Enantioselective HPLC-UV method for determination of eslicarbazepine acetate (BIA 2-093) and its metabolites in human plasma. Biomed Chromatogr (2007) 0.77
Treatment-resistant Late-life Depression: Challenges and Perspectives. Curr Neuropharmacol (2015) 0.77
Bioanalytical chromatographic methods for the determination of catechol-O-methyltransferase inhibitors in rodents and human samples: a review. Anal Chim Acta (2011) 0.77
Relationship between plasma and brain levels and the anticonvulsant effect of lamotrigine in rats. Eur J Pharmacol (2003) 0.77
Development and validation of a fast isocratic liquid chromatography method for the simultaneous determination of norfloxacin, lomefloxacin and ciprofloxacin in human plasma. Biomed Chromatogr (2010) 0.76
Venlafaxine pharmacokinetics focused on drug metabolism and potential biomarkers. Drug Metabol Drug Interact (2014) 0.76
Analytical methods for determination of new fluoroquinolones in biological matrices and pharmaceutical formulations by liquid chromatography: a review. Anal Bioanal Chem (2012) 0.76
First liquid chromatography method for the simultaneous determination of levofloxacin, pazufloxacin, gatifloxacin, moxifloxacin and trovafloxacin in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci (2013) 0.76
Herb-drug interaction of Fucus vesiculosus extract and amiodarone in rats: a potential risk for reduced bioavailability of amiodarone in clinical practice. Food Chem Toxicol (2012) 0.76
Disposition of eslicarbazepine acetate in the mouse after oral administration. Fundam Clin Pharmacol (2008) 0.76
A critical review of microextraction by packed sorbent as a sample preparation approach in drug bioanalysis. Bioanalysis (2013) 0.76
Binding of licarbazepine enantiomers to mouse and human plasma proteins. Biopharm Drug Dispos (2010) 0.75
Herb-drug pharmacokinetic interaction between carica papaya extract and amiodarone in rats. J Pharm Pharm Sci (2014) 0.75
Pharmacokinetics, brain distribution and plasma protein binding of carbamazepine and nine derivatives: new set of data for predictive in silico ADME models. Epilepsy Res (2013) 0.75
First liquid chromatographic method for the simultaneous determination of amiodarone and desethylamiodarone in human plasma using microextraction by packed sorbent (MEPS) as sample preparation procedure. J Chromatogr B Analyt Technol Biomed Life Sci (2012) 0.75
Vascular dementia by thalamic strategic infarct. Arq Neuropsiquiatr (2008) 0.75
Enantioselective assay for therapeutic drug monitoring of eslicarbazepine acetate: no interference with carbamazepine and its metabolites. Ther Drug Monit (2010) 0.75
Chronopharmacology of nebicapone, a new catechol-O-methyltransferase inhibitor. Curr Med Res Opin (2010) 0.75
A chiral liquid chromatography method for the simultaneous determination of oxcarbazepine, eslicarbazepine, R-licarbazepine and other new chemical derivatives BIA 2-024, BIA 2-059 and BIA 2-265, in mouse plasma and brain. Biomed Chromatogr (2011) 0.75
Simultaneous and enantioselective liquid chromatographic determination of eslicarbazepine acetate, S-licarbazepine, R-licarbazepine and oxcarbazepine in mouse tissue samples using ultraviolet detection. Anal Chim Acta (2007) 0.75
Probiotics prevent growth deficit of colon wall strata of malnourished rats post-lactation. An Acad Bras Cienc (2012) 0.75
An HPLC-DAD method for the simultaneous quantification of opicapone (BIA 9-1067) and its active metabolite in human plasma. Analyst (2013) 0.75
A chiral HPLC-UV method for the quantification of dibenz[b,f]azepine-5-carboxamide derivatives in mouse plasma and brain tissue: eslicarbazepine acetate, carbamazepine and main metabolites. J Sep Sci (2011) 0.75
First MEPS/HPLC assay for the simultaneous determination of venlafaxine and O-desmethylvenlafaxine in human plasma. Bioanalysis (2014) 0.75
Effect of nebicapone on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. Eur J Clin Pharmacol (2008) 0.75
Stereoselective disposition of S- and R-licarbazepine in mice. Chirality (2008) 0.75
Recent Highlights on Molecular Hybrids Potentially Useful in Central Nervous System Disorders. Mini Rev Med Chem (2016) 0.75
In-vivo evaluation of prolonged release bilayer tablets of anti-Parkinson drugs in Göttingen minipigs. J Pharm Pharmacol (2011) 0.75
Chiral chromatographic resolution of antiepileptic drugs and their metabolites: a challenge from the optimization to the application. Biomed Chromatogr (2013) 0.75
Clinical drug-drug interactions: focus on venlafaxine. Drug Metabol Personal Ther (2015) 0.75
Drug-metabolizing Enzymes and Efflux Transporters in Nasal Epithelium: Influence on the Bioavailability of Intranasally Administered Drugs. Curr Drug Metab (2016) 0.75
Can the CEIBA Cocktail Designed for Human Cytochrome P450 Enzymes be Used in the Rat for Drug Interaction Studies? J Pharm Pharm Sci (2017) 0.75